Enzymatic cleavage of a CD4 immunoadhesin generates crystallizable, biologically active Fd-like fragments. 1990

S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
Department of Recovery Process Research and Development, Genentech, Inc., South San Francisco, California 94080.

CD4, the cell-surface receptor for the human immunodeficiency virus (HIV), is a member of the immunoglobulin (Ig) gene superfamily. It contains four extracellular sequences homologous to Ig VL domains. The first of these (V1) is sufficient for binding to HIV; however, the structural basis for this binding has yet to be elucidated. While several models for the structure of Ig-like domains in CD4 have been proposed on the basis of crystal structures of Ig VL domains, direct evidence that CD4 and VL domains fold similarly has not been obtained. To produce individual domains of CD4 for structural studies, we used molecular fusions of such domains with Ig heavy chain (CD4 immunoadhesins), which are very efficiently expressed and secreted in mammalian cells and can be easily isolated in single-step purification with protein A. Since these fusion molecules are antibody-like homodimeric proteins, we investigated the possibility that they might be cleaved enzymatically to produce Fd-like and Fc fragments. We found that cleavage with papain releases an Fd-like fragment containing the V1 and V2 CD4 domains; this fragment fully retains the ability to bind to the HIV-1 envelope glycoprotein gp120 and to block HIV infection in vitro. Moreover, folding of the CD4 domains in the Fd-like fragment and in the parent immunoadhesin is indistinguishable, as indicated by circular dichroism. Spectral analysis of the Fd-like fragment suggests that secondary structure content is identical with that predicted from the known structure of Ig VL domains; this directly supports the hypothesis that the V1 and V2 domains of CD4 fold similarly to Ig VL domains.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007074 Immunoglobulin G The major immunoglobulin isotype class in normal human serum. There are several isotype subclasses of IgG, for example, IgG1, IgG2A, and IgG2B. Gamma Globulin, 7S,IgG,IgG Antibody,Allerglobuline,IgG(T),IgG1,IgG2,IgG2A,IgG2B,IgG3,IgG4,Immunoglobulin GT,Polyglobin,7S Gamma Globulin,Antibody, IgG,GT, Immunoglobulin
D008969 Molecular Sequence Data Descriptions of specific amino acid, carbohydrate, or nucleotide sequences which have appeared in the published literature and/or are deposited in and maintained by databanks such as GENBANK, European Molecular Biology Laboratory (EMBL), National Biomedical Research Foundation (NBRF), or other sequence repositories. Sequence Data, Molecular,Molecular Sequencing Data,Data, Molecular Sequence,Data, Molecular Sequencing,Sequencing Data, Molecular
D010206 Papain A proteolytic enzyme obtained from Carica papaya. It is also the name used for a purified mixture of papain and CHYMOPAPAIN that is used as a topical enzymatic debriding agent. EC 3.4.22.2. Tromasin
D010446 Peptide Fragments Partial proteins formed by partial hydrolysis of complete proteins or generated through PROTEIN ENGINEERING techniques. Peptide Fragment,Fragment, Peptide,Fragments, Peptide
D011485 Protein Binding The process in which substances, either endogenous or exogenous, bind to proteins, peptides, enzymes, protein precursors, or allied compounds. Specific protein-binding measures are often used as assays in diagnostic assessments. Plasma Protein Binding Capacity,Binding, Protein
D011487 Protein Conformation The characteristic 3-dimensional shape of a protein, including the secondary, supersecondary (motifs), tertiary (domains) and quaternary structure of the peptide chain. PROTEIN STRUCTURE, QUATERNARY describes the conformation assumed by multimeric proteins (aggregates of more than one polypeptide chain). Conformation, Protein,Conformations, Protein,Protein Conformations
D002942 Circular Dichroism A change from planar to elliptic polarization when an initially plane-polarized light wave traverses an optically active medium. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Circular Dichroism, Vibrational,Dichroism, Circular,Vibrational Circular Dichroism
D003460 Crystallization The formation of crystalline substances from solutions or melts. (McGraw-Hill Dictionary of Scientific and Technical Terms, 4th ed) Crystalline Polymorphs,Polymorphism, Crystallization,Crystal Growth,Polymorphic Crystals,Crystal, Polymorphic,Crystalline Polymorph,Crystallization Polymorphism,Crystallization Polymorphisms,Crystals, Polymorphic,Growth, Crystal,Polymorph, Crystalline,Polymorphic Crystal,Polymorphisms, Crystallization,Polymorphs, Crystalline
D006678 HIV Human immunodeficiency virus. A non-taxonomic and historical term referring to any of two species, specifically HIV-1 and/or HIV-2. Prior to 1986, this was called human T-lymphotropic virus type III/lymphadenopathy-associated virus (HTLV-III/LAV). From 1986-1990, it was an official species called HIV. Since 1991, HIV was no longer considered an official species name; the two species were designated HIV-1 and HIV-2. AIDS Virus,HTLV-III,Human Immunodeficiency Viruses,Human T-Cell Lymphotropic Virus Type III,Human T-Lymphotropic Virus Type III,LAV-HTLV-III,Lymphadenopathy-Associated Virus,Acquired Immune Deficiency Syndrome Virus,Acquired Immunodeficiency Syndrome Virus,Human Immunodeficiency Virus,Human T Cell Lymphotropic Virus Type III,Human T Lymphotropic Virus Type III,Human T-Cell Leukemia Virus Type III,Immunodeficiency Virus, Human,Immunodeficiency Viruses, Human,Virus, Human Immunodeficiency,Viruses, Human Immunodeficiency,AIDS Viruses,Human T Cell Leukemia Virus Type III,Lymphadenopathy Associated Virus,Lymphadenopathy-Associated Viruses,Virus, AIDS,Virus, Lymphadenopathy-Associated,Viruses, AIDS,Viruses, Lymphadenopathy-Associated
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
January 1980, Nucleic acids symposium series,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
November 2003, Cell death and differentiation,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
July 1978, Endocrinology,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
February 1997, Journal of molecular endocrinology,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
April 1990, Nature,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
June 1969, Japanese journal of pharmacology,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
January 1985, Survey of immunologic research,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
January 1984, Voprosy meditsinskoi khimii,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
January 1991, Methods in enzymology,
S M Chamow, and D H Peers, and R A Byrn, and M G Mulkerrin, and R J Harris, and W C Wang, and P J Bjorkman, and D J Capon, and A Ashkenazi
January 2007, Biochemistry. Biokhimiia,
Copied contents to your clipboard!